Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26816592 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2DPP4 | |
| SCHEMBL26782680 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2DPP4 | |
| SCHEMBL18023493 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2DPP4 | |
| SCHEMBL16006532 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2DPP4 | |
| SCHEMBL29102312 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2DPP4 | |
| SCHEMBL1572414 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2DPP4 | |
| SCHEMBL19664035 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2DPP4 | |
| SCHEMBL1293236 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2DPP4 | |
| SCHEMBL29102387 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2DPP4 | |
| SCHEMBL1293235 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137674-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR | INCYTE CORP (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026090323-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR AND ITS USE IN THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090333-A1 | COMBINATION USING A KRAS G12D INHIBITOR AND CHEMOTHERAPY COMBINATIONS AS WELL AS THEIR USE IN THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250304601-A1 | Processes for Preparing KRAS Inhibitors | INCYTE CORPORATION | 2025-10-02 | — | — | US | disclosed |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2025080589-A1 | PROCESSES FOR PREPARING KRAS INHIBITORS | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025080593-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR AND PD-1 INHIBITOR OR PD-L1 INHIBITOR | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025080592-A1 | COMBINATION COMPRISING A KRAS G12D INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025080585-A1 | CRYSTALLINE FORMS OF 3-(1-(( 1 R,4R,5S)-2-AZABICYCLO[2.1.1 ]HEXAN-5-YL)-2-(( 1 R,3R,5R)-2-( CYCLOPROPANECARBONYL)-2-AZABICYCLO[3.1.0]HEXAN-3-YL)-7-(2,3-DICHLOROPHENYL)-6-FLUORO-4-METHYL-1 H-PYRROLO[3,2-C]QUINOLIN-8-YL)PROPANENITRILE | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2023064857-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009054791-A1 | FUSED PYRROLIDINE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| US-20090111820-A1 | FUSED PYRROLIDINE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111820-A1 | FUSED PYRROLIDINE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009054793-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | CHRM2 3661/4885CHRM1 3517/4885CHRM3 3507/4885 |
| US-20090111820-A1 | FUSED PYRROLIDINE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | CHRM2 1852/4885CHRM1 1404/4885CHRM3 1107/4885 |
| US-20250304601-A1 | Processes for Preparing KRAS Inhibitors | KRAS, NRAS, HRAS | CHRM2 4871/4885CHRM1 4859/4885CHRM3 4861/4885 |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | CHRM2 1222/4885CHRM1 1043/4885CHRM3 737/4885 |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | CHRM2 4782/4885CHRM1 4747/4885CHRM3 4777/4885 |
| US-20260137674-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR | KRAS, NRAS, DCTD | CHRM2 4587/4885CHRM1 4603/4885CHRM3 4786/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CHRM2 4782/4885CHRM1 4747/4885CHRM3 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.